Analysts Set Adaptimmune Therapeutics PLC – (NASDAQ:ADAP) PT at $8.00

Shares of Adaptimmune Therapeutics PLC – (NASDAQ:ADAP) have been assigned a consensus recommendation of “Hold” from the seven brokerages that are currently covering the stock, Marketbeat reports. Four equities research analysts have rated the stock with a hold rating and three have issued a buy rating on the company. The average 1 year price objective among analysts that have issued ratings on the stock in the last year is $7.00.

A number of equities analysts recently weighed in on the stock. Citigroup lowered their price target on shares of Adaptimmune Therapeutics from $8.00 to $5.00 and set a “buy” rating on the stock in a research report on Monday, April 27th. Zacks Investment Research cut shares of Adaptimmune Therapeutics from a “buy” rating to a “hold” rating in a report on Friday. BidaskClub cut shares of Adaptimmune Therapeutics from a “buy” rating to a “hold” rating in a report on Tuesday, July 7th. Mizuho boosted their price target on shares of Adaptimmune Therapeutics from $3.00 to $9.00 and gave the stock a “neutral” rating in a report on Monday, June 1st. Finally, SVB Leerink reiterated a “market perform” rating on shares of Adaptimmune Therapeutics in a report on Thursday, May 14th.

In other Adaptimmune Therapeutics news, Director James Noble sold 500,000 shares of the company’s stock in a transaction on Friday, May 29th. The shares were sold at an average price of $9.33, for a total transaction of $4,665,000.00. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, CFO Gavin Wood acquired 33,000 shares of the business’s stock in a transaction on Monday, June 29th. The shares were purchased at an average price of $1.62 per share, with a total value of $53,460.00. Following the transaction, the chief financial officer now owns 33,000 shares in the company, valued at approximately $53,460. The disclosure for this purchase can be found here. 18.89% of the stock is currently owned by corporate insiders.

Institutional investors and hedge funds have recently made changes to their positions in the company. Tower Research Capital LLC TRC increased its holdings in shares of Adaptimmune Therapeutics by 5,820.4% in the 1st quarter. Tower Research Capital LLC TRC now owns 9,591 shares of the biotechnology company’s stock valued at $26,000 after purchasing an additional 9,429 shares in the last quarter. Squarepoint Ops LLC purchased a new position in shares of Adaptimmune Therapeutics during the 1st quarter worth about $34,000. Raymond James & Associates raised its holdings in Adaptimmune Therapeutics by 13.7% in the fourth quarter. Raymond James & Associates now owns 29,411 shares of the biotechnology company’s stock valued at $35,000 after buying an additional 3,546 shares during the period. Lindbrook Capital LLC raised its holdings in Adaptimmune Therapeutics by 332.6% in the second quarter. Lindbrook Capital LLC now owns 4,058 shares of the biotechnology company’s stock valued at $41,000 after buying an additional 3,120 shares during the period. Finally, Invesco Ltd. purchased a new stake in shares of Adaptimmune Therapeutics during the first quarter valued at approximately $47,000. Institutional investors and hedge funds own 72.13% of the company’s stock.

Shares of NASDAQ ADAP traded up $0.35 during mid-day trading on Tuesday, hitting $9.35. 699,198 shares of the company’s stock traded hands, compared to its average volume of 803,719. The company’s 50-day moving average is $9.43 and its two-hundred day moving average is $5.63. The company has a market capitalization of $1.22 billion, a P/E ratio of -7.14 and a beta of 2.41. Adaptimmune Therapeutics has a 1 year low of $0.71 and a 1 year high of $13.40.

Adaptimmune Therapeutics (NASDAQ:ADAP) last announced its earnings results on Thursday, May 14th. The biotechnology company reported ($0.24) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.25) by $0.01. Adaptimmune Therapeutics had a negative net margin of 7,324.48% and a negative return on equity of 85.62%. The firm had revenue of $0.76 million for the quarter, compared to analysts’ expectations of $25.90 million. On average, equities analysts expect that Adaptimmune Therapeutics will post -0.97 EPS for the current fiscal year.

About Adaptimmune Therapeutics

Adaptimmune Therapeutics plc, a clinical-stage biopharmaceutical company, focuses on providing novel cell therapies primarily to patients with solid tumors in the United States. The company's specific peptide enhanced affinity receptor T-cell platform enables it to identify cancer targets. It is involved in developing ADP-A2M10 that is in the phase I clinical trials for the treatment of non-small cell lung cancer (NSCLC), as well as urothelial, melanoma, and head and neck cancers; ADP-A2M4 that is in phase I clinical trial for solid tumor indication that include urothelial, melanoma, head and neck, ovarian, NSCLC, esophageal, gastric, synovial sarcoma, and myxoid round cell liposarcoma cancers; and ADP-A2AFP that is in phase I clinical trial for hepatocellular carcinoma.

Featured Story: Do stock splits help investors?

Receive News & Ratings for Adaptimmune Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Adaptimmune Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.